Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMC-P115C
- Development stage
- Phase 1
- Lead developer
- Immunocore
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
IMC-P115C is a half-life extended (HLE) ImmTAC (Immune mobilizing monoclonal TCRs Against Cancer) bispecific protein developed by Immunocore. It targets the PReferentially expressed Antigen in MElanoma (PRAME) peptide presented by HLA-A*02:01 and engages CD3 on T cells, redirecting the immune system to recognize and kill cancer cells. The molecule is designed to improve patient convenience by reducing dosing frequency compared to earlier candidates. IMC-P115C uses the same CD3 effector and TCR specificity as brenetafusp, another Immunocore candidate, but with an extended half-life for less frequent administration. Its mechanism of action involves high-affinity binding to intracellular PRAME antigens via engineered soluble T cell receptors, coupled with anti-CD3 immune activation for targeted tumor cell killing. The drug is currently being evaluated in a Phase 1 clinical trial for patients with advanced solid tumors expressing PRAME who are HLA-A*02:01-positive[1][4][5][6][7].
- Other names
- PRAME-HLE-A02PRAME-HLE-A-02PRAME-HLE-A 02
02
Targets
PRAME peptide–HLA complexCD3 (T-cell surface glycoprotein CD3)PRAME (Preferentially expressed antigen in melanoma)
Beyond the preview
Go deeper on IMC-P115C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMC-P115C.